The therapeutic potential of I-domain integrins.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-94-017-9153-3_11PMID 25023174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular composition and function of integrin-based collagen glues-introducing COLINBRIs.

  2014cited by this paper
• Propofol Shares the Binding Site with Isoflurane and Sevoflurane on Leukocyte Function–Associated Antigen-1

  2013cited by this paper
• Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury.

  2013cited by this paper
• Identification of α2β1 integrin inhibitor VP-i with anti-platelet properties in the venom of Vipera palaestinae.

  2013cited by this paper
• MicroRNA regulation of integrins.

  2013cited by this paper
• Arresten, a Collagen-Derived Angiogenesis Inhibitor, Suppresses Invasion of Squamous Cell Carcinoma

  2012cited by this paper
• Random phage-epitope library based identification of a peptide antagonist of Mac-1 β2 integrin ligand binding.

  2012cited by this paper
• Integrin α1/Akita double knockout mice on a Balb/c background develop advanced features of human diabetic nephropathy

  2012cited by this paper
• Novel α2β1 Integrin Inhibitors Reveal That Integrin Binding to Collagen under Shear Stress Conditions Does Not Require Receptor Preactivation*

  2012cited by this paper
• The Collagen-binding Integrin α2β1 Is a Novel Interaction Partner of the Trimeresurus flavoviridis Venom Protein Flavocetin-A

  2012cited by this paper
• Vixapatin (VP12), a C-Type Lectin-Protein from Vipera xantina palestinae Venom: Characterization as a Novel Anti-angiogenic Compound

  2012cited by this paper
• Rhinocetin, a Venom-derived Integrin-specific Antagonist Inhibits Collagen-induced Platelet and Endothelial Cell Functions

  2012cited by this paper
• Fibroproliferative Disorders and Their Mechanobiology

  2012cited by this paper
• Upregulated Expression of Integrin α1 in Mesangial Cells and Integrin α3 and Vimentin in Podocytes of Col4a3-Null (Alport) Mice

  2012cited by this paper
• Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

  2012cited by this paper
• A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.

  2012cited by this paper
• Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study

  2012cited by this paper
• Enhancing Integrin α1 Inserted (I) Domain Affinity to Ligand Potentiates Integrin α1β1-mediated Down-regulation of Collagen Synthesis*

  2012cited by this paper
• TSC2 modulates cell adhesion and migration via integrin-α1β1.

  2012cited by this paper
• The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss

  2012cited by this paper
• The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer.

  2011cited by this paper
• Monoclonal antibodies reveal the alteration of the rhodocetin structure upon α2β1 integrin binding.

  2011cited by this paper
• Endorepellin, the Angiostatic Module of Perlecan, Interacts with Both the α2β1 Integrin and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)

  2011cited by this paper
• Small Molecule–Mediated Activation of the Integrin CD11b/CD18 Reduces Inflammatory Disease

  2011cited by this paper
• Role of integrin α1 subunits in gastric cancer patients with peritoneal dissemination.

  2011cited by this paper
• Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521).

  2010cited by this paper
• Integrins as therapeutic targets: lessons and opportunities

  2010cited by this paper
• Prophylactic uses of integrin CD18-βA peptide in a murine polymicrobial peritonitis model

  2010cited by this paper
• Structure of an integrin with an αI domain, complement receptor type 4

  2010cited by this paper
• Alpha2beta1 integrin is the major collagen‐binding integrin expressed on human Th17 cells

  2010cited by this paper
• Integrins in cancer: biological implications and therapeutic opportunities

  2010cited by this paper
• An LFA-1 (αLβ2) Small-Molecule Antagonist Reduces Inflammation and Joint Destruction in Murine Models of Arthritis

  2010cited by this paper
• Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

  2010cited by this paper
• Efalizumab binding to the LFA-1 αL I domain blocks ICAM-1 binding via steric hindrance

  2009cited by this paper
• Crystal structure of isoflurane bound to integrin LFA‐1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems

  2009cited by this paper
• Osteopontin Enhances Phagocytosis through a Novel Osteopontin Receptor, the αXβ2 Integrin1

  2009cited by this paper
• Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors

  2009cited by this paper
• Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists.

  2009cited by this paper
• T cell activation.

  2009cited by this paper
• Agonizing integrin antagonists?

  2009cited by this paper
• Cardiac myofibroblast differentiation is attenuated by alpha(3) integrin blockade: potential role in post-MI remodeling.

  2009cited by this paper
• Small-molecule inhibitors of integrin α2β1 that prevent pathological thrombus formation via an allosteric mechanism

  2009cited by this paper
• Selective binding of integrins from different renal cell types to the NC1 domain of alpha3 and alpha1 chains of type IV collagen.

  2009cited by this paper
• A small-molecule inhibitor of integrin α2β1 introduces a new strategy for antithrombotic therapy

  2009cited by this paper
• Bacteria hijack integrin-linked kinase to stabilize focal adhesions and block cell detachment

  2009cited by this paper
• Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

  2009cited by this paper
• Structure of the F‐spondin domain of mindin, an integrin ligand and pattern recognition molecule

  2009cited by this paper
• A key role for the integrin alpha2beta1 in experimental and developmental angiogenesis.

  2009cited by this paper
• The α2β1 integrin‐specific antagonist rhodocetin is a cruciform, heterotetrameric molecule

  2009cited by this paper
• Structural requirements of KTS-disintegrins for inhibition of alpha(1)beta(1) integrin.

  2009cited by this paper
• Effect of VP12 and viperistatin on inhibition of collagen receptors: dependent melanoma metastasis

  2009influential reference
• Integrins in angiogenesis and lymphangiogenesis

  2008cited by this paper
• New coumarin‐based anti‐inflammatory drug: putative antagonist of the integrins αLβ2 and αMβ2

  2008cited by this paper
• Structural basis for distinctive recognition of fibrinogen γC peptide by the platelet integrin αIIbβ3

  2008cited by this paper
• Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

  2008cited by this paper
• Integrin subunit CD18 Is the T-lymphocyte receptor for the Helicobacter pylori vacuolating cytotoxin.

  2008cited by this paper
• C‐reactive protein binds to αIIbβ3

  2008cited by this paper
• RTX cytotoxins recognize β2 integrin receptors through N-linked oligosaccharides

  2008cited by this paper
• Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer

  2008cited by this paper
• Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug

  2008cited by this paper
• A role for leukocyte-endothelial adhesion mechanisms in epilepsy

  2008cited by this paper
• Integrins: the keys to unlocking angiogenesis.

  2008cited by this paper
• Characterization of two novel LPS-binding sites in leukocyte integrin betaA domain.

  2007cited by this paper
• Rotavirus-neutralizing antibodies inhibit virus binding to integrins alpha 2 beta 1 and alpha 4 beta 1.

  2007cited by this paper
• KTS and RTS-Disintegrins: Anti-Angiogenic Viper Venom Peptides Specifically Targeting the α1β 1 Integrin

  2007cited by this paper
• A critical role of LFA-1 in the development of Th17 cells and induction of experimental autoimmune encephalomyelytis.

  2007cited by this paper
• Efalizumab in the treatment of discoid lupus erythematosus.

  2007cited by this paper
• Collagen receptors as potential targets for novel anti-platelet agents.

  2007cited by this paper
• Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

  2007cited by this paper
• Integrins and cancer.

  2007cited by this paper
• Monomeric Expression of Bovine β2-Integrin Subunits Reveals Their Role in Mannheimia haemolytica Leukotoxin-Induced Biological Effects

  2007cited by this paper
• A Phase I/II Randomized Open‐Label Multicenter Trial of Efalizumab, a Humanized Anti‐CD11a, Anti‐LFA‐1 in Renal Transplantation

  2007cited by this paper
• Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold.

  2007cited by this paper
• Virtual Screening Leads to the Discovery of an Effective Antagonist of Lymphocyte Function‐Associated Antigen‐1

  2007cited by this paper
• Rotavirus-neutralizing antibodies inhibit virus binding to integrins α2β1 and α4β1

  2007cited by this paper
• Human CD18 Is the Functional Receptor for Aggregatibacter actinomycetemcomitans Leukotoxin

  2007cited by this paper
• Cell integrins: commonly used receptors for diverse viral pathogens.

  2007cited by this paper
• Polymorphisms and haplotypes of integrinalpha1 (ITGA1) are associated with bone mineral density and fracture risk in postmenopausal Koreans.

  2007cited by this paper
• KTS and RTS-disintegrins: anti-angiogenic viper venom peptides specifically targeting the alpha 1 beta 1 integrin.

  2007cited by this paper
• Characterization of two novel LPS‐binding sites in leukocyte integrin βA domain

  2007cited by this paper
• CLinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate‐to‐severe plaque psoriasis: results from a phase III international randomized, placebo‐controlled trial

  2006cited by this paper
• A Small Molecule Agonist of an Integrin, αLβ2*

  2006cited by this paper
• Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101)--a small molecule antagonist of leukocyte function associated antigen-1.

  2006cited by this paper
• Affinity enhancement of an in vivo matured therapeutic antibody using structure‐based computational design

  2006cited by this paper
• AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes

  2006cited by this paper
• An orally active, primate selective antagonist of LFA-1 inhibits delayed-type hypersensitivity in a humanized-mouse model.

  2006cited by this paper
• Competition between intercellular adhesion molecule‐1 and a small‐molecule antagonist for a common binding site on the αl subunit of lymphocyte function‐associated antigen‐1

  2006cited by this paper
• Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis

  2006cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant Inhibitor for integrin alphavbeta3.

  2006cited by this paper
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

  2006cited by this paper
• A small molecule agonist of an integrin, alphaLbeta2.

  2006cited by this paper
• Integrin α3β1, a Novel Receptor for α3(IV) Noncollagenous Domain and a Trans-dominant Inhibitor for Integrin αvβ3*

  2006cited by this paper
• Therapeutic anti‐integrin (α4 and αL) monoclonal antibodies: two‐edged swords?

  2005cited by this paper
• Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

  2005cited by this paper
• Rotaviruses interact with α4β7 and α4β1 integrins by binding the same integrin domains as natural ligands

  2005cited by this paper
• 1,4-Diazepane-2,5-diones as novel inhibitors of LFA-1.

  2005cited by this paper
• Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

  2005cited by this paper
• cDNA Cloning and Functional Expression of Jerdostatin, a Novel RTS-disintegrin from Trimeresurus jerdonii and a Specific Antagonist of the α1β1 Integrin*

  2005cited by this paper
• New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism

  2005cited by this paper

• Incorporation of Natural and Recombinant Collagen Proteins within Fmoc-Based Self-Assembling Peptide Hydrogels

  2022cites this paper
• The Biology of Myxofibrosarcoma: State of the Art and Future Perspectives

  2020cites this paper
• How not to discover a drug - integrins

  2020cites this paper
• RGD-Binding Integrins in Head and Neck Cancers

  2017cites this paper
• Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.

  2016cites this paper
• Recruitment of calcineurin to the TCR positively regulates T cell activation

  2016cites this paper
• Contribution of collagen adhesion receptors to tissue fibrosis

  2016cites this paper
• Biologic treatment in Sjögren's syndrome.

  2014cites this paper